PARP inhibitors and newly second primary malignancies in cancer patients: a systematic review and safety meta-analysis of placebo randomized controlled trials

Ann Oncol. 2021 Aug;32(8):1048-1050. doi: 10.1016/j.annonc.2021.04.023. Epub 2021 Jun 6.
No abstract available

Publication types

  • Letter
  • Meta-Analysis
  • Systematic Review

MeSH terms

  • Humans
  • Neoplasms* / drug therapy
  • Neoplasms* / epidemiology
  • Neoplasms, Second Primary* / chemically induced
  • Neoplasms, Second Primary* / drug therapy
  • Neoplasms, Second Primary* / epidemiology
  • Poly(ADP-ribose) Polymerase Inhibitors / adverse effects
  • Randomized Controlled Trials as Topic

Substances

  • Poly(ADP-ribose) Polymerase Inhibitors